Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paromomycin vs Metronidazole for Symptomatic Dientamoeba Fragilis (COMFORTER)
NCT06907498Recruiting
- Sponsor
- Sheba Medical Center
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of paromomycin in Dientamoeba fragilis infection (2 arms), sponsored by Sheba Medical Center. Primary endpoint: Clinical improvement or resolution at 30 days. Started Jan 2024; status: recruiting.
02
Drugs
paromomycin
03
Conditions
Dientamoeba fragilis infection
Beyond the preview
Go deeper on NCT06907498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907498.